This week in Dermatology

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic therapy for chronic inflammatory skin disease, the rising burden of bullous pemphigoid, and pediatric care alongside treatment resistance in scabies and melanoma. Let's dive in.

We start with systemic treatment, where this week's papers cover both new efficacy data and the practical questions of safety and partial response. In Nature Medicine, Ezzedine and colleagues report the paired phase 3 STOP-V trials of povorcitinib, an oral, highly selective JAK1 inhibitor taken once daily at 30 milligrams, in adults with moderate-to-severe nonsegmental vitiligo [1]. Across roughly 900 patients, both trials met their primary endpoint of at least 75 percent improvement in the facial vitiligo score at one year. About 19 percent of treated patients reached that bar, compared with roughly 7 percent and 3 percent on placebo, meaning the odds of response roughly tripled in one trial and rose about sevenfold in the other. Overall adverse event rates were similar to placebo; acne stood out, affecting about one in ten treated patients versus around three percent on placebo, and JAK class-specific events were absent or rare. The absolute response rate is modest, and this is one-year data, but it is phase 3 evidence for an oral repigmentation option in patients who are candidates for systemic therapy, a group with few alternatives. On the safety side of biologics, Alabas and colleagues, writing in the Journal of the European Academy of Dermatology and Venereology, used the British BADBIR registry linked to national cancer data to follow nearly nineteen thousand people with moderate-to-severe psoriasis [2]. After excluding cancers diagnosed in the first year, biologic initiators had no higher risk of cancer, or of keratinocyte carcinoma, than patients starting non-biologic systemic drugs, and the IL-12/23 and IL-17 inhibitors did not differ from TNF inhibitors. The authors are explicit that follow-up for the newer classes is shorter, so this is reassuring observational evidence rather than a final word on long-term risk.

Two papers address patients who respond incompletely. In Acta Dermato-Venereologica, Heratizadeh and colleagues drew on the TREATgermany registry of 476 patients with atopic dermatitis on dupilumab [3]. Only about four percent of patients were poor responders, defined as an eczema area and severity improvement of 40 percent or less across two follow-up visits within the first year, while just under half of patients were stable responders. Poor responders were more often male, smokers, hypertensive and heavier. With only 19 poor responders, these are candidate risk factors that the authors say need translational confirmation. In hidradenitis suppurativa, where up to half of patients on licensed biologics respond only partially, Lynch and colleagues in JAMA Dermatology tested a pragmatic algorithm at a French tertiary center [4]. Patients whose disease flared before the next injection, the so-called end-of-dose effect, had their biologic intensified; those without it had antibiotics added. Across 107 patients, just over half of patients reached the primary IHS4 response at three to five months, and improvement held at six to twelve months in 65 patients. A hint favoring intensification on flare duration did not survive correction for multiple comparisons. This is a single-center retrospective cohort without a control arm, so the end-of-dose effect is best viewed as a plausible phenotyping tool awaiting prospective testing.

Our second theme is bullous pemphigoid, which two population studies frame as both growing and partly drug-driven. In the Journal of the European Academy of Dermatology and Venereology, Meyer and colleagues analyzed German insurance claims covering 6.8 million people from 2010 to 2023 [5]. Prevalence tripled over that period, with the steepest climb in people over 80. Patients with pemphigoid carried more comorbidity than matched controls and had roughly three times the mortality, with close to one in five dying within a year. First-year healthcare costs were nearly four times higher, driven mainly by inpatient care, and systemic corticosteroids were prescribed to almost three quarters of patients. In the journal Dermatology, Ahle Erichsen and colleagues add a nationwide Danish case-control study of about 2,500 pemphigoid cases matched to a quarter of a million controls [6]. Current use of a DPP-4 inhibitor was linked to more than five times the odds of pemphigoid, while other diabetes drugs showed no comparable signal. The association varied by agent: vildagliptin and linagliptin carried roughly ten times the odds, whereas sitagliptin's signal was considerably weaker. Read together, these studies describe an ageing population increasingly exposed to a known trigger, and the drug-specific Danish estimates add useful nuance, though as case-control data they show association rather than proof that switching agents changes risk.

Turning to pediatrics, Belmesk and colleagues in Pediatric Dermatology reviewed 58 children with nasal tip infantile hemangiomas, a high-risk location for disfigurement [7]. At age three, fibroadipose residua were seen in under half of propranolol-treated children versus over ninety percent of untreated children, and every untreated child had some sequela. Higher doses above 2.5 milligrams per kilogram per day offered no added benefit, and the authors conclude that about 2 milligrams per kilogram per day appears sufficient in most cases, with topical timolol adding little. The cohort is small, retrospective and spans sixteen years, but it reinforces the case for early systemic propranolol at this site. Also in Pediatric Dermatology, Zaenglein and colleagues report a PeDRA Delphi consensus on combined oral contraceptives for acne in patients under 16 [8]. The abstract describes the concerns the multidisciplinary panel weighed, including pubertal development, weight, bone health, cancer risk and psychiatric effects, but does not summarize the recommendations themselves, so the full text will matter here. It is expert opinion rather than trial evidence, filling a gap where safety in younger patients has not been established.

Our final theme is treatment resistance. In the Journal of the European Academy of Dermatology and Venereology, Akhoundi and colleagues sequenced scabies mites from patients in France, Belgium, Tunisia and Madagascar [9]. Among 45 confirmed cases, just over half of the specimens carried one of three sodium channel mutations, and these were found in patients with documented permethrin failure, while patients without the mutations were treated successfully. M918L was the most widespread. It is a small pilot, and one of the variants is synonymous with uncertain function, but it gives a molecular basis to the clinical reports of permethrin failure and supports resistance surveillance. In melanoma, Amaria and colleagues in Nature Medicine pooled early trials of amsoki-cel, a tumor-infiltrating lymphocyte therapy engineered with membrane-bound IL-15 that is switched on by acetazolamide, removing the need for interleukin-2 [10]. The first patient developed rapid lymphocyte expansion and swelling around an irradiated brain metastasis, prompting substantial dose reductions before careful re-escalation. Across 37 patients with checkpoint-resistant disease, there were no dose-limiting toxicities, ICU admissions or treatment-related deaths, though high-grade cytopenias were common. At the recommended dose, two thirds of the 15 patients responded, including two complete responses. Numbers are very small and single-arm, and a pivotal phase 2 cohort is ongoing.

If you only have time for one paper this week, make it the STOP-V trials of povorcitinib in Nature Medicine [1]. Two concordant phase 3 trials settle that an oral JAK1 inhibitor can deliver facial repigmentation in nonsegmental vitiligo, while reopening the question of how modest absolute response rates should be weighed against long-term systemic exposure.

That's your roundup for This Week in Dermatology. The full transcript and references are available on the episode page. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.